Epidemiology & Clinical Spectrum

Irritable bowel syndrome (IBS) affects ~10–15% of the global population, with a 2:1 female-to-male predominance. It is classified into subtypes based on stool morphology (Bristol Stool Scale):

• IBS-C: Constipation-predominant
• IBS-D: Diarrhea-predominant
• IBS-M (or IBS-A): Mixed/alternating stool pattern
• Unsubtyped (IBS-U)

Pathophysiological underpinnings include:

• Visceral hypersensitivity: Amplified afferent signaling from gut to CNS, often mediated by mast cell–enteric neuron interactions.
• Gut motility disturbances: Accelerated transit in IBS-D, delayed in IBS-C.
• Microbiota dysbiosis: Reduced Faecalibacterium prausnitzii, increased Proteobacteria; emerging role of viral/fungal components.
• Low-grade immune activation: Elevated mucosal CD3+ T cells and mast cells (especially post-infectious IBS [PI-IBS]).
• Brain–gut axis dysfunction: Altered default mode network connectivity on fMRI, HPA axis hyperreactivity to stress.

Precipitating factors:

• PI-IBS: Occurs in 5–30% after acute infectious gastroenteritis (most commonly Campylobacter, Salmonella, Shigella, or Giardia). Risk enhanced by prolonged fever, prolonged antimicrobial use, and psychological stress during infection.
• Overlap disorders: Functional dyspepsia (40–60% of IBS patients), gastroparesis, chronic pelvic pain.
• Psychosocial triggers: Anxiety/depression comorbid in >50%; trauma history increases risk 3-fold.

Diagnostic Evaluation: A Precision Medicine Approach

1. Rome IV Criteria (Required for Diagnosis)

IBS is diagnosed when recurrent abdominal pain, on average, at least 1 day/week in the last 3 months (new diagnostic window), associated with two or more of:

• Pain related to defecation
• Onset associated with a change in stool frequency
• Onset associated with a change in stool form (appearance)

Note: Symptoms must have started ≥6 months prior. Rome IV eliminates the “discomfort” descriptor, emphasizing pain as key for central sensitization assessment.

2. Red Flags & Alarm Features: When to Investigate

Strong recommendation (AGA/ACG 2021): Do not label IBS without excluding organic pathology in patients with:

Important nuance: IBS-D with nocturnal stools is rarely functional—investigate first.

3. Laboratory & Stool Testing (Tiered Approach)

• CBC/ESR/CRP: Mandatory first-line to detect anemia, inflammation (↑CRP/ESR suggests IBD over IBS; specificity >90% for excluding active IBD).
• Fecal calprotectin / lactoferrin:
  • Cut-off <50 µg/g: Highly predictive of functional disorder (IBS) with NPV >95%.
  • Cut-off >100–150 µg/g: warrants colonoscopy (ACG 2021, ECCO 2023).
    Note: False ↑ in NSAID users, diverticulosis, or microscopic colitis.
• Celiac serology (tTG-IgA + total IgA):
  • Prevalence of celiac in IBS = 2–4% (vs. ~1% general population).
  • Must test BEFORE gluten exclusion—false negatives if patient is already on GFD.
  • Positive serology → confirm with duodenal biopsy ( Marsh classification).
• Bile acid diarrhea (BAD) workup:
  • Consider if chronic diarrhea + cholecystectomy, ileal resection, or diabetes.
  • First-line: Fecal bile acid measurement (HPLC-MS), but limited availability.
  • Practical alternative: Therapeutic trial of bile acid sequestrant (e.g., cholestyramine 4g TID).
  • Selenohomocholic acid (SECA) scan (available in Europe): Gold standard for SeHCY test alternatives.
  • Eligible for eluxadoline only if BAD ruled out (due to pancreatitis risk).
• Hydrogen/methane breath testing:
  • For suspected SIBO: Controversial. Current ACG (2020) and World Gastroenterology Organization (2023) advise against routine use due to high false positives.
  • Methane-positive IBS-C may benefit from rifaximin + neomycin.

4. Advanced Testing (Indicated Only for Refractory Cases)

• Colonic transit studies (wireless motility capsule or radiopaque markers): For refractory constipation to distinguish slow-transit vs. Outlet obstruction.
• Anorectal manometry ± balloon expulsion test: Diagnostic gold standard for pelvic floor dysfunction (dyssynergia).
  • Key finding: Absent or paradoxical puborectalis contraction during simulated defecation.

Management: Stratified, Mechanism-Directed Therapy

I. First-Line: Lifestyle & Dietary Modifications

• Fiber:
  • Soluble fiber (psyllium): 10–30 g/day improves global symptoms and stool consistency (RR 1.7; NNT=5) (AGA 2021 Strong Recommendation).
  • Avoid insoluble fiber (wheat bran): May worsen bloating/gas via osmotic load and fermentation.
• Dietary education:
  • Limit caffeine, alcohol, fatty foods (stimulates colonic motility via CCK), and carbonated beverages.
  • Low-FODMAP diet:
    • Evidence: Meta-analysis (Moayyedi et al., Gastroenterology 2023): 54–76% symptom improvement vs. 14–38% with control diets.
    • Protocol: Strict elimination for 2–6 weeks → systematic reintroduction to identify triggers.
    • Caution: Risk of reduced microbial diversity; must be supervised by dietitian. Not for underweight patients or eating disorders.

II. Symptom-Directed Pharmacotherapy

| IBS-D | Loperamide | 2–4 mg PRN, max 16 mg/day; avoid in nocturnal diarrhea | Strong | | | Rifaximin (for bloating/diarrhea, SIBO-like) | 550 mg TID × 14 days; repeat if recurrent after ≥4 weeks | Conditional (strongest for methane-negative IBS-D) | | | Eluxadoline | 75–100 mg BID only in patients with intact gallbladder; contraindicated post-cholecystectomy (pancreatitis risk ↑ 2.6×) | Conditional | | | Alosetron (5-HT3 antagonist) | 0.5–1 mg BID; restricted to severe IBS-D in women via REMS program | Conditional (FDA black box for ischemic colitis) | | | Antibiotics: Neomycin + rifaximin for methane-dominant SIBO | Based on breath testing | Conditional |

III. Visceral Analgesia & Neuromodulation

• Low-dose tricyclic antidepressants (TCAs):
  • Amitriptyline 10–50 mg nightly: Reduces pain via inhibition of serotonin/norepinephrine reuptake and muscarinic blockade.
  • Evidence: RCT (Evers et al., Lancet Gastroenterol Hepatol 2022): 48% ≥30% pain reduction vs 29% placebo.
  • Advantage over SSRIs: More effective for visceral pain; minimal GI side effects at low doses.
• CBT/ERP/Hypnotherapy:
  • Gut-directed hypnotherapy: 70–80% response rate (Keene et al., Clin Gastroenterol Hepatol 2023).
  • Online CBT platforms (e.g., “MyIBSLife”) now covered by some insurers.

IV. Emerging & Adjunctive Therapies

• Probiotics:
  • Evidence: Meta-analysis (Hoon et al., Am J Gastroenterol 2023): Multi-strain probiotics (esp. Bifidobacterium infantis 35624) improve global symptoms (NNT=8). Single strains less effective.
• Antimicrobial phytotherapies: Berberine, oregano oil—limited RCT data; not standard.
• Fecal microbiota transplantation (FMT): Not recommended outside research (RCTs show no benefit over placebo in unselected IBS; JAMA 2021).

Longitudinal Management Principles

1. Reassurance & education: “This is a real disorder with physiological basis—your gut is sensitive, but not damaged.”
2. Shared decision-making: Align treatment with patient goals (e.g., symptom control vs. microbiome optimization).
3. Step-up care model: Start low-risk therapies → escalate only if inadequate response after 4–8 weeks.
4. Avoid over-testing: In non-alarm patients meeting Rome IV criteria, extensive labs/imaging reduces quality of life and increases costs without benefit (AGA “Choose Wisely” initiative).

Key Take-Home Messages for Clinicians

✅ Diagnosis: Rome IV + exclude red flags. Fecal calprotectin is the best blood-free rule-out test for IBD.
✅ IBS-D with nocturnal stools? Think BAD or organic disease—not IBS.
✅ Linaclotide/plecanatide are first-line for IBS-C; rifaximin for IBS-D bloating/diarrhea.
✅ Low-dose amitriptyline and gut-directed hypnotherapy have the strongest evidence for refractory symptoms.
✅ Low-FODMAP diet is effective but requires expert guidance to prevent nutritional deficits.

Sources: ACG Clinical Guideline: IBS (2021), ECCO Consensus (2023), AGA Institute Review (2024), Cochrane Database Syst Rev (Fiber, 2023; Probiotics, 2024).